Disease Landscape and Forecast Insights

Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…

Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…

The number total of prevalent cases of MCI across the European countries under study will increase by 21%, from 5.2 million in 2020 to 6.3 million in 2029. Among the countries considered…

The number of total prevalent cases of MCI across the countries under study will increase by 39%, from 2.8 million in to 3.9 million in 10 years. Among the countries considered in this…

The number of total prevalent cases of MCI across the countries under study will increase by 43%, from 58 million in 2020 to 83 million in 2030. Among the countries considered in this…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…

Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will…